Activity Stream
@moatrx
• 3 weeks ago
Posted a new blog:
UK MYASTHENIA GRAVIS COMPETITIVE INTELLIGENCE
UK MYASTHENIA GRAVIS COMPETITIVE INTELLIGENCE
NICE rejected efgartigimod outright in 2025, leaving rozanolixizumab as the FcRn class's one still-untested bid for UK access.
An estimated 7,000-10,000 UK...
